Vertex Pharmaceuticals, Inc. (VRTX) Misses Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $516.34 --0%
EPS Growth %: -0.6%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
LGCY, UXIN, SCHL, More
EPS Growth %: -0.6%
Financial Fact:
Royalty revenues: 3.84M
Today's EPS Names:
LGCY, UXIN, SCHL, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stitch Fix (SFIX) Tops Q4 EPS by 4c; Offers Guidance
- Piper Sandler Starts Ares Management, L.P. (ARES) at Overweight
- Emkay Global Upgrades Gail (India) Ltd. (GAIL:IN) (GAILF) to Buy (1)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
